{"entity":{"id":"nct04196465","kind":"trial","name":"Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers","aka":[],"tldr":"A phase 2 trial of IMC-001 run by Asan Medical Center, active and no longer recruiting.","summary":"Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers is a phase 2 interventional study registered as NCT04196465 by Asan Medical Center, with 48 participants planned, started 2019-09-09. Conditions recorded: Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer and Subjects With Resectable Liver Cancer. Interventions recorded: IMC-001.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04196465","url":"https://clinicaltrials.gov/study/NCT04196465"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["imc-001"],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04196465","phase":"2","setting":"Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(Neo-Chance Study)","sponsor":"Asan Medical Center","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04196465/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"imc-001","kind":"drug","name":"IMC-001","route":"/drugs/imc-001/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}